Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,094

Document Document Title
WO/2020/097635A1
The invention provides an improved method for the production of Scopolamine by extraction.  
WO/2020/063696A1
Provided are a preparation of amine urea sensitive amine oxidase inhibitor and the use thereof. In particular, dislosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof. Also...  
WO/2020/063320A1
The application provides a method for improving the stability of a low-concentration atropine ophthalmic preparation, as well as a method for preparing the ophthalmic preparation, an atropine ophthalmic preparation prepared thereby and a...  
WO/2020/047312A1
This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of di...  
WO/2020/035464A1
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...  
WO/2020/027723A1
The present disclosure relates to derivatives of bicyclic compounds and their uses in therapy. In particular, the present disclosure relates to derivatives of bicyclic compounds for use in modulating kinase enzymatic activity and accordi...  
WO/2020/022323A1
A compound of formula (I):wherein Ring A, Q, R1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,X, a,b, c and d are as defined in the specification.  
WO/2020/012427A1
The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising the compound...  
WO/2020/006296A1
The present invention is directed towards compounds having the Formula (lb) or the Formulae (III) and pharmaceutically acceptable salts, solvates and clathrates thereof, compositions thereof, as well as towards the use of said compounds ...  
WO/2019/243414A1
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.  
WO/2019/243850A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions...  
WO/2019/241292A1
Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.  
WO/2019/226490A1
Provided is a compound of Formula (I), wherein the variable groups are defined herein.  
WO/2019/214656A1
A fluorine-containing isoxazole compound, a preparation method therefor, and a pharmaceutical composition and use thereof. Specifically, disclosed is a compound represented by general formula I or enantiomers or diastereoisomers thereof,...  
WO/2019/210879A1
The present invention relates to a bicyclic nucleocapsid inhibitor and use thereof as a drug for treating hepatitis B. Specifically, disclosed is a compound which can be used as an HBV inhibitor and has a structure represented by chemica...  
WO/2019/212937A1
The present invention relates to pyridazinones and related compounds of Formula I which are inhibitors of PARP7 and are useful in the treatment of cancer.  
WO/2019/199972A1
Described herein are splice modifying compounds affecting splicing of mRNA, such as pre-mRNA, expressed from the FOXM1 gene, compositions comprising thereof, and methods using the same.  
WO/2019/189555A1
Provided is a compound that can have a CDK12-inhibiting effect and that is expected to be useful as a preventive or therapeutic drug for cancer and the like. The compound or salt thereof is represented by formula (I) (where each symbol i...  
WO/2019/126253A8
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/143508A1
Efficient methods are provided for large scale production of ethyl cocaine-free cocaine hydrochloride. Compositions and methods comprising administration of cocaine hydrochloride are provided.  
WO/2019/141096A1
Provided is a substituted urea compound, and a preparation method and use thereof. More particularly, the invention relates to a substituted urea compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorphic substance, a ...  
WO/2019/126253A1
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/110521A1
The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...  
WO/2019/104011A1
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...  
WO/2019/099307A1
The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...  
WO/2019/084383A1
The invention provides a compound of formula (I): (Formula (I)) or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a cryst...  
WO/2019/079626A1
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by...  
WO/2019/040106A3
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.  
WO/2019/040105A3
The present disclosure relates to compounds according to Formula (I), treating diseases.  
WO/2019/031618A8
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...  
WO/2019/040105A2
The present disclosure relates to compounds according to Formula (I), treating diseases.  
WO/2019/038656A1
The present invention relates to parenteral formulations comprising Palonosetron, NK1 receptor antagonist and a corticosteroid. The present invention also relates to process of preparing such formulations.  
WO/2019/040106A2
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.  
WO/2019/040107A1
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.  
WO/2019/036384A1
The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as can...  
WO/2019/031618A1
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...  
WO/2019/021140A1
The present technology relates to molecules that stimulate the immune system for use in treating drug abuse and addiction, and to the methods of synthesis thereof. Said molecules comprise a calixarene chemical structure, preferably calix...  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2018/235813A1
A compound represented by the formula, which has an RORĪ³t inhibiting effect and is useful as a prophylactic or therapeutic agent for autoimmune diseases, allergic diseases, etc., or a salt thereof.  
WO/2018/168643A1
Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...  
WO/2018/154596A1
Provided herein is a process for synthesis of tiotropium bromide wherein the coupling of scopine with 2, 2-dithienyl glycolate is achieved by a two step process under mild conditions.  
WO/2018/151678A1
The present invention relates to heterocyclic compounds having the general Formula (I) wherein W1, W2, W3, W4, W7, W8, R1, R2, R3, R4, X2, X3, X4, Z1, Z2, Z3, Q, n and m are as defined herein, or a pharmaceutically acceptable salt thereo...  
WO/2018/145216A1
An herbal pharmaceutical compositions of California poppy and methods for the treatment of sleep disorders and dream-related disorders is disclosed. The formulation may be in the form of capsules, tablets, caplets or other oral dosage fo...  
WO/2018/124001A1
The present invention pertains to novel, exceptional low-molecular compounds that specifically antagonize the BMP signaling pathway, and because these compounds can be used to modulate cell growth, differentiation, proliferation, and apo...  
WO/2018/115591A1
Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(...  
WO/2018/084817A3
The present invention relates to a new crystalline form of an active agent, the preparation processes of said crystalline form, the pharmaceutical compounds containing said crystalline form and the use of said compounds in the treatment ...  
WO/2018/084817A2
The present invention relates to a new crystalline form of an active agent, the preparation processes of said crystalline form, the pharmaceutical compounds containing said crystalline form and the use of said compounds in the treatment ...  
WO/2018/083101A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/083103A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/055642A1
Provided herein is a process for synthesis of tiotropium bromide and a process for synthesis of scopine starting from a dimethyl tartarate compound. The synthetic sequence comprises a double Mannich reaction (Robinson-Schopf reaction).  

Matches 1 - 50 out of 3,094